94 related articles for article (PubMed ID: 15911705)
21. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
Ballantyne CM; Weiss R; Moccetti T; Vogt A; Eber B; Sosef F; Duffield E;
Am J Cardiol; 2007 Mar; 99(5):673-80. PubMed ID: 17317370
[TBL] [Abstract][Full Text] [Related]
22. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
[TBL] [Abstract][Full Text] [Related]
23. New light on statin side effects. What recent research on the cholesterol drugs means to you.
Heart Advis; 2005 Aug; 8(8):3. PubMed ID: 16193557
[No Abstract] [Full Text] [Related]
24. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
[TBL] [Abstract][Full Text] [Related]
25. Is Jupiter also a god of primary prevention?
Accad M; Fred HL
Tex Heart Inst J; 2010; 37(1):6-7. PubMed ID: 20200621
[No Abstract] [Full Text] [Related]
26. Rosuvastatin receives FDA approval.
Cardiovasc J S Afr; 2003; 14(5):286. PubMed ID: 14664234
[No Abstract] [Full Text] [Related]
27. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
Roth EM; Rosenson RS; Carlson DM; Fukumoto SM; Setze CM; Blasetto JW; Khurmi NS; Stolzenbach JC; Williams LA
Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):421-8. PubMed ID: 20953684
[TBL] [Abstract][Full Text] [Related]
28. JUPITER, rosuvastatin, and the European Medicines Agency.
Ridker PM; Glynn RJ
Lancet; 2010 Jun; 375(9731):2071. PubMed ID: 20494436
[No Abstract] [Full Text] [Related]
29. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
[TBL] [Abstract][Full Text] [Related]
30. Rosuvastatin calcium.
Quirk J; Thornton M; Kirkpatrick P
Nat Rev Drug Discov; 2003 Oct; 2(10):769-70. PubMed ID: 14579811
[No Abstract] [Full Text] [Related]
31. Dangers of rosuvastatin identified before and after FDA approval.
Wolfe SM
Lancet; 2004 Jun; 363(9427):2189-90. PubMed ID: 15220045
[No Abstract] [Full Text] [Related]
32. Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database.
Palmer MK; Nicholls SJ; Lundman P; Barter PJ; Karlson BW
Eur J Prev Cardiol; 2013 Dec; 20(6):1080-7. PubMed ID: 23644489
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of rosuvastatin.
Olsson GO
Lancet; 2004 Jul 10-16; 364(9429):135. PubMed ID: 15246717
[No Abstract] [Full Text] [Related]
34. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
Ballantyne CM; Hoogeveen RC; Raya JL; Cain VA; Palmer MK; Karlson BW;
Atherosclerosis; 2014 Jan; 232(1):86-93. PubMed ID: 24401221
[TBL] [Abstract][Full Text] [Related]
36. Should rosuvastatin be withdrawn from the market?
Kastelein JJ
Lancet; 2004 Oct 30-Nov 5; 364(9445):1577-8; author reply 1578-9. PubMed ID: 15519620
[No Abstract] [Full Text] [Related]
37. Cholesterol medication makes a debut in the U.S.
Heart Advis; 2003 Oct; 6(10):2. PubMed ID: 15106543
[No Abstract] [Full Text] [Related]
38. Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
Vaziri ND; Liang K
Am J Nephrol; 2004; 24(6):606-13. PubMed ID: 15583480
[TBL] [Abstract][Full Text] [Related]
39. Studies examine inflammatory biomarker in prevention and prediction of heart disease.
Mitka M
JAMA; 2009 Jan; 301(1):23-4. PubMed ID: 19126804
[No Abstract] [Full Text] [Related]
40. Effects of once weekly rosuvastatin among patients with a prior statin intolerance.
Backes JM; Moriarty PM; Ruisinger JF; Gibson CA
Am J Cardiol; 2007 Aug; 100(3):554-5. PubMed ID: 17659946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
